<DOC>
	<DOCNO>NCT02521493</DOCNO>
	<brief_summary>This phase III trial study response-based chemotherapy treat newly diagnose acute myeloid leukemia myelodysplastic syndrome younger patient Down syndrome . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Response-based chemotherapy separate patient different risk group treat accord respond first course treatment ( Induction I ) . Response-based treatment may effective treat acute myeloid leukemia myelodysplastic syndrome younger patient Down syndrome reduce side effect .</brief_summary>
	<brief_title>Response-Based Chemotherapy Treating Newly Diagnosed Acute Myeloid Leukemia Myelodysplastic Syndrome Younger Patients With Down Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine 2-year event-free-survival ( EFS ) child standard risk Down syndrome ( DS ) acute myeloid leukemia ( AML ) ( minimal residual disease [ MRD ] -negative one cycle induction therapy ) elimination high dose ( HD ) Ara-C ( cytarabine ) treatment regimen . II . To determine 2-year EFS child high risk DS AML ( MRD-positive one cycle induction therapy ) intensification treatment equivalent use high risk AML child without DS . EXPLORATORY OBJECTIVES : I . To determine extent elimination HD Ara-C treatment standard risk DS AML decrease adverse event resource utilization . II . To determine elimination HD Ara-C treatment standard risk DS AML result significant decrease number day per patient spent protocol therapy compare predecessor study AAML0431 . III . To determine elimination HD Ara-C treatment standard risk DS AML result significant decrease average number day hospitalization per patient compare predecessor study AAML0431 A2971 . IV . To determine elimination HD Ara-C treatment standard risk DS AML result significant decrease number ( per patient ) rate ( per duration treatment ) sterile site infection compare predecessor study AAML0431 . V. To determine elimination HD Ara-C treatment standard risk DS AML result significant decrease resource utilization AML treatment compare predecessor study AAML0431 . VI . To compare feasibility analytical characteristic flow cytometry , polymerase chain reaction ( PCR ) target error-corrected sequencing GATA binding protein 1 ( globin transcription factor 1 ) ( GATA1 ) mutation method detect MRD DS AML . VII . To establish DS AML cell bank viably frozen bone marrow sample collect end induction correspond non-tumor deoxyribonucleic acid ( DNA ) sample collect end Induction 1 . OUTLINE : INDUCTION I : Patients receive cytarabine intrathecally ( IT ) day 1 intravenously ( IV ) continuously 96 hour , daunorubicin hydrochloride IV 1-15 minute , thioguanine orally ( PO ) twice daily ( BID ) day 1-4 . Induction I continue minimum 28 day . Patients assign 1 2 treatment arm base MRD status completion Induction I . ARM A ( STANDARD RISK ) : INDUCTION II : Patients receive cytarabine IV continuously 96 hour , daunorubicin hydrochloride IV 1-15 minute , thioguanine PO BID day 1-4 . Induction II continue minimum 28 day . INDUCTION III : Patients receive cytarabine , daunorubicin hydrochloride , thioguanine Induction II . Induction III continue minimum 28 day . INTENSIFICATION I : Patients receive cytarabine IV continuously 168 hour day 1-7 etoposide IV 60-120 minute day 1-3 . Intensification I continue minimum 28 day . INTENSIFICATION II : Patients receive cytarabine etoposide Intensification I. Intensification II continue minimum 28 day . ARM B ( HIGH RISK ) : INDUCTION II : Patients receive high dose cytarabine IV 1-3 hour BID day 1-4 mitoxantrone hydrochloride IV 15-30 minute day 3-6 . Induction II continue minimum 28 day . INTENSIFICATION I : Patients receive high dose cytarabine IV 1-3 hour BID etoposide IV 60-120 minute day 1-5 . Intensification I continue minimum 28 day . INTENSIFICATION II : Patients receive high dose cytarabine IV 3 hour BID day 1 , 2 , 8 , 9 . Patients also receive asparaginase asparaginase Erwinia chrysanthemi ( E. carotovora ) intramuscularly ( IM ) IV 30 minute day 2 9 . Intensification II continue minimum 28 day . After completion study treatment , patient follow 1 month , monthly 12 month , every 3 month 12 month , every 6 month 3 year , annually 5 year , relapse .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>Patients must constitutional trisomy 21 ( Down syndrome ) trisomy 21 mosaicism ( karyotype fluorescence situ hybridization [ FISH ] ) Patients previously untreated de novo AML meet criterion AML &gt; = 20 % bone marrow blast set World Health Organization ( WHO ) Myeloid Neoplasm classification Patients cytopenias and/or bone marrow blast meet criteria diagnosis AML ( WHO Myeloid Neoplasm classification ) &lt; 20 % marrow blast eligible meet criterion diagnosis myelodysplastic syndrome ( MDS ) Patients history transient myeloproliferative disorder ( may may require chemotherapy intervention ) , : Are &gt; 8 week since resolution transient myeloproliferative disease ( TMD ) &gt; = 5 % blast , OR Patients sho increase blast count ( &gt; = 5 % ) serial bone marrow aspirate perform least 4 week apart Children previously receive chemotherapy , radiation therapy antileukemic therapy eligible protocol , exception cytarabine treatment TMD There minimal organ function requirement enrollment study Note : Previous cardiac repair sufficient cardiac function exclusion criterion Each patient 's parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human subject research must meet Patients promyelocytic leukemia ( FrenchAmericanBritish [ FAB ] M3 ) Prior therapy Patients = &lt; 30 day last dose cytarabine use treatment TMD</criteria>
	<gender>All</gender>
	<minimum_age>91 Days</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>